A Phase 3 interventional study of Alirocumab and Placebo (for alirocumab) in Hypercholesterolemia, sponsored by Sanofi. Completed at 91 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-08.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 10th largest by enrollment, is one of 12 that started in 2012, is one of 20 in phase 3, and was the 13th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 486 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 11th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 15th registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
Primary Objective of the study:
To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo.
Secondary Objectives:
The maximum study duration was planned to be 89 weeks per participant including participants who successfully completed the 78-week treatment period had the possibility to join an open-label extension study (LTS13463, NCT01954394) at the end of the treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
Drug: Placebo (for alirocumab) · Drug: Lipid Modifying Therapy (LMT)
Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.
Drug: Alirocumab · Drug: Lipid Modifying Therapy (LMT)
Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Also known as: SAR236553, REGN727, Praluent
Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis
Very high CV risk participants: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents. High CV risk participants: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \<60 ml/minute/1.73 m\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of ≤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or a family history of premature CHD). Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.
Time frame: Up to Week 52
Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On- Treatment Analysis
Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.
Time frame: Up to Week 52
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
Adjusted percentages at Week 24 from multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: Up to Week 52
Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.
Time frame: Up to Week 52
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis
Adjusted LS means and standard errors at Week 78 from MMRM including all available post-baseline data from Week 4 to Week 78 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 78
Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 78
The study was conducted at 89 centers in 14 countries. A total of 597 participants were screened between July 2012 and April 2013, 111 of whom were screen failures.
| Milestone | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Started | 163 | 323 |
| Treated | 163 | 322 |
| Completed | 130 | 246 |
| Not completed | 33 | 77 |
| Withdrew: Randomized but not treated | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Participants moved | 1 | 5 |
| Withdrew: Adverse event | 10 | 13 |
| Withdrew: Poor compliance to protocol | 4 | 10 |
| Withdrew: Consent withdrawn by participant | 2 | 6 |
| Withdrew: Related to study drug administration | 0 | 2 |
| Withdrew: Last visit outside protocol visit window | 14 | 26 |
| Withdrew: Site closure | 1 | 7 |
| Withdrew: Death | 0 | 4 |
| Withdrew: Other than specified above | 0 | 3 |
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis | 9.1 ± 2.2 | -48.8 ± 1.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | 8.8 ± 2.2 | -49.3 ± 1.6 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | 5.7 ± 2 | -43.5 ± 1.4 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis | 5.7 ± 2 | -43.9 ± 1.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis | 4.7 ± 1.6 | -41.1 ± 1.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis | 4.5 ± 1.7 | -41.4 ± 1.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis | 9.6 ± 2 | -42.8 ± 1.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis | 9.4 ± 2 | -43.3 ± 1.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis | 7.3 ± 1.5 | -31.4 ± 1.1 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 - ITT Analysis | 3.1 ± 1.5 | -34.5 ± 1.1 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | 5.3 ± 1.8 | -38.4 ± 1.3 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | 4.1 ± 1.4 | -28.3 ± 1 |
Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis | 9 ± 2.6 | -47.1 ± 1.9 |
Very high CV risk participants: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents. High CV risk participants: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \<60 ml/minute/1.73 m\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of ≤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or a family history of premature CHD). Adjusted percentages at Week 24 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.
| percentage of participants | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis | 2.4 | 72.2 |
Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.
| percentage of participants | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On- Treatment Analysis | 2.4 | 73 |
Adjusted percentages at Week 24 from multiple imputation approach model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percentage of participants | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis | 0.8 | 59.8 |
Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 i.e. up to 21 days after last injection.
| percentage of participants | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis | 0.8 | 60.1 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis | -7.5 ± 2 | -25.2 ± 1.4 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | 0.8 ± 1.2 | 8.8 ± 0.9 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | 6.3 ± 2.2 | -9.6 ± 1.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis | 0.3 ± 1 | 5 ± 0.7 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis | -3.9 ± 1.8 | -21.2 ± 1.3 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis | 2.1 ± 1.2 | 6.4 ± 0.8 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis | 1.7 ± 2.2 | -8 ± 1.6 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis | 0.1 ± 1 | 2.9 ± 0.7 |
Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis | 9.1 ± 2.6 | -48.1 ± 1.9 |
Adjusted LS means and standard errors at Week 78 from MMRM including all available post-baseline data from Week 4 to Week 78 regardless of status on-or off-treatment.
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis | 11.5 ± 2.8 | -40.3 ± 2.0 |
Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 (i.e. up to 21 days after last injection).
| percent change | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis | 14.0 ± 2.8 | -43.7 ± 2.0 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit in the study regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 22/163 (13.5%) | 70/163 (42.9%) |
| Alirocumab 75/Up to 150 mg Q2W | — | 44/322 (13.7%) | 142/322 (44.1%) |
| Event | Placebo | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/163 | 4/322 |
| Angina unstableCardiac disorders | 2/163 | 2/322 |
| Atrial fibrillationCardiac disorders | 2/163 | 1/322 |
| Acute myocardial infarctionCardiac disorders | 1/163 | 3/322 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/163 | 3/322 |
| SyncopeNervous system disorders | 1/163 | 2/322 |
| Angina pectorisCardiac disorders | 1/163 | 2/322 |
| Cardiac failure congestiveCardiac disorders | 1/163 | 2/322 |
| BradycardiaCardiac disorders | 0/163 | 2/322 |
| Miscarriage of partnerSocial circumstances | 0/163 | 2/322 |
| Event | Placebo | Alirocumab 75/Up to 150 mg Q2W |
|---|---|---|
| Injection site reactionGeneral disorders | 18/163 | 40/322 |
| NasopharyngitisInfections and infestations | 12/163 | 36/322 |
| Upper respiratory tract infectionInfections and infestations | 14/163 | 22/322 |
| MyalgiaMusculoskeletal and connective tissue disorders | 11/163 | 6/322 |
| InfluenzaInfections and infestations | 9/163 | 20/322 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 9/163 | 20/322 |
| Back painMusculoskeletal and connective tissue disorders | 7/163 | 18/322 |
| BronchitisInfections and infestations | 9/163 | 10/322 |
| HeadacheNervous system disorders | 9/163 | 15/322 |
| SinusitisInfections and infestations | 7/163 | 17/322 |
| Age, Continuous(years) | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 51.7 ± 12.3 | 52.1 ± 12.9 | 51.9 ± 12.7 |
| Sex: Female, Male(Participants) | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Female | 69 | 143 | 212 |
| Male | 94 | 180 | 274 |
| Calculated LDL-C in mg/dL(mg/dL) | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 144.4 ± 46.8 | 144.8 ± 51.1 | 144.6 ± 49.7 |
| Calculated LDL-C in mmol/L(mmol/L) | Placebo | Alirocumab 75 mg/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 3.739 ± 1.213 | 3.749 ± 1.325 | 3.746 ± 1.287 |
The record gives a start of Jul 2012, a primary completion of Apr 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 7 months after primary completion. A results delay was requested in Feb 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab